B and T lymphocyte attenuator (BTLA) and PD-1 pathway dual blockade promotes antitumor immune responses by reversing CD8+ T-cell exhaustion in non-small cell lung cancer

B and T lymphocyte attenuator (BTLA) and PD-1 pathway dual blockade promotes antitumor immune responses by reversing CD8+ T-cell exhaustion in non-small cell lung cancer

BackgroundImmunotherapies targeting the programmed cell death 1 (PD-1)/programmed death ligand 1 (PD-L1) have shown great promise for a subset of patients with non-small cell lung cancer (NSCLC). However, safe and robust combination therapies are still needed to bring the benefit to broader patient...

Full description

Saved in:
Bibliographic Details
Main Authors: Yang Zhang, Yang Yang, Yuanyuan Zeng, Qiuxia Qu, Dan Shen, Chuanyong Mu, Wei Lei, Meiqin Su, Jingyu Mao, Lirong Gao, Zeyi Liu, Cheng Chen, Jian-an Huang
Format: Article
Language:English
Published: Frontiers Media S.A. 2025-05-01
Series:Frontiers in Immunology
Subjects:
NSCLC
BTLA
PD-1/PD-L1
immunotherapy
combination
Online Access:https://www.frontiersin.org/articles/10.3389/fimmu.2025.1553042/full
Tags: Add Tag
No Tags, Be the first to tag this record!

Similar Items

Similar Items